SAN FRANCISCO, CA, TippingPoint Biosciences, a drug discovery company, announced a pre-seed investment.
TippingPoint Biosciences, a therapeutic company focused on innovative drug discovery targeting the aberrant DNA in cancer cells, announced pre-seed investment from the Pediatric Brain Tumor Foundation, Sontag Foundation, Yuvaan Tiwari Foundation, and BrightEdge, the impact investment and venture capital arm of the American Cancer Society.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
